Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hahn Pledges FDA Independence While Maintaining Role On Warp Speed

Executive Summary

FDA Commissioner Stephen Hahn will participate in discussions or considerations of Operation Warp Speed, but won’t be involved in specific decisions or recommendations of the COVID-19 countermeasures public-private partnership to preserve agency independence, he said. The approach is less black and white than other agency officials, but may be acceptable given a commissioner’s more limited role in specific product reviews. Still, some worried about lines becoming blurred. 

You may also be interested in...



Speed Of Coronavirus Vaccine Development May Hurt Public Confidence

Vaccine developers worry that the focus on development speed may embolden anti-vaccine movement and hurt public willingness to get a COVID-19 shot if one is approved.

Coronavirus Update: White House Picks Five Vaccines For US Operation Warp Speed

An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'. 

Hahn Defends Using Less ‘Robust’ Data During COVID, But Critics Contend It Has Gone Too Far

US FDA Commissioner Hahn says agency's choice to make fast decisions on less robust data sets during COVID-19, paired with constantly reevaluating these decisions drives best public health outcomes. But critics argue the agency may be pushing the bar too low and needs to be more transparent about the evidence it is using for emergency use authorizations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel